Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Higher credit stress for big four bank
Shares fall after announcement that capital will be replenished for loan impairment provisions.
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.30 | 28.90 | -0.31% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,387.46 | 26.39 | 0.10% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,596.10 | 771.21 | 1.31% |
| NZX 50 Index | 12,892.76 | 22.69 | -0.18% |
| S&P 500 | 7,109.14 | 16.92 | -0.24% |
| S&P/ASX 200 | 8,936.20 | 33.30 | -0.37% |
| SSE Composite Index | 4,068.59 | 13.53 | -0.33% |